Inhibitors of RAS-effector protein interactions
US11724999B2 · kind B2 · utility
0Cited by
4References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 23, 2019 |
| Grant date | Aug 15, 2023 |
| Priority date | — |
| Expiry date | Jan 23, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.